Peptinovo
Ann Arbor, US · 3 known investors
Find your way into Peptinovo
145 people in our graph share verified history with the Peptinovo team — schools, employers, funds. One of them is your warm intro.
Safa Rashtchyunlockedknows BILL ELLIOTT · together at Purdue University (overlapped)
×4knows the team · via Stony Brook University
knows the team · via Purdue University
×2knows the team · via Baylor College of Medicine
×2knows the team · via Calvin University
knows the team · via University of Massachusetts Medical School
Peptinovo develops PALM™, a targeted drug-delivery platform that encapsulates chemotherapy drugs to deliver them directly to cancer cells while sparing healthy tissue, reducing side effects and enabling higher therapeutic doses. The technology mimics HDL cholesterol carriers that cancer cells naturally uptake, allowing selective destruction of tumors with improved safety profiles.
Founders & leadership
RH
Ren HomaninFounderRen Homan spent over three decades in drug discovery and development at Parke-Davis, Pfizer, and Esperion Therapeutics, and previously co-founded AlphaCore Pharma, which was acquired by AstraZeneca in 2013. He is Chief Scientific Officer of Peptinovo Biopharma, where he oversees research advancement of the company's drug-delivery platform.
RH
REYNOLD HOMANExecutive
BE
BILL ELLIOTTinExecutiveBill Elliott has held roles in oncology drug discovery and development at Parke Davis/Pfizer and ProNAi Therapeutics, as well as preclinical and contract research positions at Charles River Discovery and Imaging Services and BioDuro.
ST
STEVE TOKAZExecutive
Board
DR
DAVID ROMENESCOBoard director
FB
FRED BROWNBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 2 rounds · 2021–2024
▶$1.3MraisedDec 2024 · 12 investors · BiotechnologyRule 506(c)
▶$1.3MraisedDec 2024 · 12 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- DAVID ROMENESCODirector
- FRED BROWNDirector
- REYNOLD HOMANExecutive Officer, Director
- BILL ELLIOTTExecutive Officer
- STEVE TOKAZExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$955KraisedJun 2021 · 12 investors · BiotechnologyRule 506(b)
▶$955KraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEVE TOKAZDirector
- REYNOLD HOMANExecutive Officer, Director
- Amount sold
- $955K
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Clinovo7 shared keywordsClinovo provides staff augmentation services for pharmaceutical and biotech sponsors, embedding specialized clinical research professionals such as CRAs, data managers, and regulatory specialists directly into sponsor teams on a flexible basis. The company serves clinical trial sponsors seeking to scale internal teams with regulated expertise without permanent hiring overhead.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Synnovation Therapeutics4 shared keywordsA drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
Northwest Biotherapeutics3 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Vitanova Biomedical3 shared keywordsVitanova Biomedical develops cancer treatments based on a proprietary light-activated intracellular acidosis (LAIA) therapy that uses upconverting nanoparticles and deep-penetrating light to induce cancer cell death. The company operates in the biomedical and oncology therapeutics space.
Companies competing with Peptinovo for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Peptinovo do?
- Peptinovo develops PALM™, a targeted drug-delivery platform that encapsulates chemotherapy drugs to deliver them directly to cancer cells while sparing healthy tissue, reducing side effects and enabling higher therapeutic doses. The technology mimics HDL cholesterol carriers that cancer cells naturally uptake, allowing selective destruction of tumors with improved safety profiles.
- Who founded Peptinovo?
- Peptinovo was founded by Ren Homan.
- Who are Peptinovo's investors?
- Peptinovo's investors include ID Ventures, WMU Biosciences Research & Commercialization Center, CANTILEVER INVESTORS.
- How much funding has Peptinovo raised?
- Peptinovo has disclosed $2.3M raised across 2 rounds.
- Where is Peptinovo headquartered?
- Peptinovo is headquartered in Ann Arbor, US.